In agreement, inhibiting T-Like Cell-Originated Protein Kinase (TOPK), which is a protein in the MAPK/ERK pathway that also modulates the PI3K/AKT pathway, leads to decreased FOXM1 gene expression in ovarian cancer cells [155]. Here, AKT1 is linked to ovarian cancer.